Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 26,313 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 26,313 shares of Tempus AI stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Tuesday, August 18th, James William Rogers sold 22,529 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $1,117,663.69.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $66.65 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The firm’s 50-day moving average price is $52.44 and its two-hundred day moving average price is $51.21. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The stock has a market capitalization of $12.03 billion, a P/E ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business’s revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.22) earnings per share. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Victory Capital Management Inc. raised its stake in Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after acquiring an additional 162 shares in the last quarter. Truist Financial Corp grew its stake in shares of Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after purchasing an additional 194 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after purchasing an additional 219 shares during the period. SeaCrest Wealth Management LLC increased its holdings in shares of Tempus AI by 3.7% during the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after purchasing an additional 229 shares during the period. Finally, Geneos Wealth Management Inc. raised its stake in shares of Tempus AI by 29.4% during the fourth quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock valued at $65,000 after purchasing an additional 250 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TEM. HC Wainwright lowered their price objective on Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Lake Street Capital cut Tempus AI to a “hold” rating in a research note on Monday, July 20th. Guggenheim boosted their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Wolfe Research started coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and an average price target of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.